CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Income Statement [Abstract]
Net revenues	$ 73,309	$ 52,125	$ 248,069
Cost of revenues	19,814	18,238	80,048
Gross profit	53,495	33,887	168,021
Operating costs and expenses:
Research, development and clinical trials	17,042	11,104	50,574
Sales and marketing	22,333	18,135	77,663
General and administrative	20,238	17,325	73,456
Total operating costs and expenses	59,613	46,564	201,693
Operating income (loss)	(6,118)	(12,677)	(33,672)
Financial expenses (income), net	2,371	4,853	12,270
Income (loss) before income taxes	(8,489)	(17,530)	(45,942)
Income taxes	3,661	3,194	17,617
Net income (loss)	$ (12,150)	$ (20,724)	$ (63,559)
Basic and diluted net income (loss) per ordinary share	$ (0.13)	$ (0.23)	$ (0.69)
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share	94,811,282	89,985,612	91,828,043